Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects

ClinicalTrials.gov ID: NCT02198651

Public ClinicalTrials.gov record NCT02198651. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects (PREDICTRA)

Study identification

NCT ID
NCT02198651
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
AbbVie
Industry
Enrollment
149 participants

Conditions and interventions

Interventions

  • Adalimumab Biological
  • Placebo Other

Biological · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 4, 2015
Primary completion
May 2, 2018
Completion
Aug 7, 2018
Last update posted
Jun 24, 2019

2015 – 2018

United States locations

U.S. sites
13
U.S. states
13
U.S. cities
13
Facility City State ZIP Site status
J Michael Grelier Research /ID# 149772 Tuscaloosa Alabama 35406
Westlake Medical Research (WMR) Clinical Trials /ID# 155386 Thousand Oaks California 91360-3994
University of Florida /ID# 144851 Jacksonville Florida 32209
North Georgia Rheumatology Grp /ID# 155225 Lawrenceville Georgia 30045
The Arthritis & Diabetes Clinic, Inc. /ID# 149017 Monroe Louisiana 71203
Aa Mrc Llc /Id# 151933 Grand Blanc Michigan 48439
North Mississippi Med Clinics /ID# 149443 Tupelo Mississippi 38801
Montefiore Medical Center /ID# 155013 The Bronx New York 10461
Shanahan Rheuma & Immuno /ID# 148689 Raleigh North Carolina 27617
Altoona Ctr Clinical Res /ID# 148448 Duncansville Pennsylvania 16635
Low Country Rheumatology, PA /ID# 154198 Summerville South Carolina 29486
West Tennessee Research Inst /ID# 148391 Jackson Tennessee 38305
Arthritis Centers of Texas /ID# 152843 Dallas Texas 75246

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 57 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02198651, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 24, 2019 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02198651 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →